J&J Spent $415 Million on This Eye Gene Therapy. MeiraGTx Just Bought It Back for $25 Million.

This is a bit like a movie that bombs at the box office but gets rave reviews from critics. The commercial scorecard said one thing, but the people closest to the data saw something else. Whether regulators agree is the billion-dollar question.

MeiraGTx plans to file for approval in both the U.S. and EU immediately, targeting a potential launch in 2027 if everything goes smoothly. That's an aggressive timeline for a program whose pivotal trial technically failed, but the company clearly believes the secondary data package is strong enough to make the case.

Follow the Money

Reacquiring bota-vec wasn't the only thing MeiraGTx announced that day. The company also priced a $100 million public stock offering at $9 per share, giving it the cash to fund the regulatory push and a potential commercial launch.

The stock has had a wild ride. Shares traded between $4.55 and $9.88 over the past year, and the offering was priced near the top of that range. Wall Street analysts seem cautiously optimistic: the consensus rating sits at Moderate Buy, with average price targets between $23 and $26. That implies analysts see the stock roughly tripling from current levels. Of course, analyst targets and reality don't always travel in the same zip code.

MeiraGTx also brings a major structural advantage to the table. The company completed process performance qualification (PPQ) for manufacturing bota-vec, meaning it can produce the therapy in-house. In gene therapy, where manufacturing is often the hardest and most expensive bottleneck, owning your own production is like a restaurant growing its own ingredients. It keeps costs down and timelines under control.

The Bigger Picture: A Platform, Not Just a Product

Bota-vec isn't MeiraGTx's only iron in the fire. The company has been assembling a broader ophthalmology platform that includes multiple late-stage programs.

In November 2025, Eli Lilly signed a deal worth $75 million upfront (with milestones exceeding $400 million) for rights to AAV-AIPL1, another MeiraGTx gene therapy targeting Leber congenital amaurosis type 4, a devastating form of childhood blindness. That deal also gave Lilly access to MeiraGTx's technology toolkit: intravitreal capsids (virus shells designed for injection into the eye's interior), AI-generated promoters (genetic switches that control where and when a gene turns on), and a riboswitch platform that lets doctors dial gene expression up or down with an oral pill.

In February 2026, MeiraGTx added another piece by licensing geographic atrophy therapies from ZipBio. The company is clearly building something bigger than any single product.

A Lonely Road With Few Competitors

The ocular gene therapy space is surprisingly sparse at the commercial stage. Luxturna, made by Spark Therapeutics (now owned by Roche), remains the only approved gene therapy for an inherited retinal disease. It treats a different condition, RPE65-mediated Leber congenital amaurosis, and has been on the market since 2017.

Behind Luxturna, the pipeline is crowded but early. More than 75 companies are developing over 80 AAV-based gene therapy candidates targeting inherited retinal diseases, with AAV-based approaches dominating about 90% of the pipeline. Competitors include REGENXBIO (partnered with AbbVie), Adverum Biotechnologies, 4D Molecular Therapeutics, and Beacon Therapeutics. But most of these programs are in Phase 2 or earlier.

If MeiraGTx can convince regulators that bota-vec's secondary data justifies approval, it could become only the second ocular gene therapy to reach patients. That's a powerful position in a market with massive unmet need.

The Bottom Line

This deal is a fascinating bet. MeiraGTx is wagering $25 million (plus $100 million in fresh capital) that J&J was wrong to give up on bota-vec. The Phase 3 miss is a real obstacle, and there's no guarantee the FDA or EMA will be persuaded by secondary endpoints when the primary one fell short.

But there's a reason the company jumped at this. They know the data better than anyone, they own the manufacturing, and they have the clinical relationships to make a regulatory case. At $25 million for a program that was valued at $415 million just three years ago, the risk-reward math is hard to argue with.

Sometimes the best deals in biotech aren't the ones that make headlines at signing. They're the ones that get quietly returned to sender.

The Biotech Field That Didn't Exist a Decade Ago Just Got Its Biggest Bet Yet

Storm Therapeutics just raised $56 million and dosed the first patient in a Phase 2 sarcoma trial, all for a drug targeting an enzyme most people have never heard of. It's the biggest clinical milestone yet for epitranscriptomics, a therapeutic field that literally didn't exist a decade ago.